Home/Investors/ARCH Venture Partners

ARCH Venture Partners

Biotech Investor · 50 portfolio companies

Portfolio
50
Combined Value
$15.5B
Focus Areas
54
Top Stage
preclinical

Portfolio Companies

CompanyValuation
Scholar Rock Holding$5.7B
Scholar Rock$5.6B
Erasca$3.3B
Prime Medicine$578.0M
Neumora Therapeutics$340.7M
Blank Bio
CellThera AI
Hua Medicine
Rome Therapeutics
Rezo Therapeutics
Altos Labs
InduPro
Perimeter Systems, Inc.
Human Immunology Biosciences (HI-Bio)
Seaport Therapeutics
Kardigan
Bitterroot Bio
Lifordi Immunotherapeutics
Synchron
Magnet Biomedicine
Dispatch Bio
Be Biopharma
Protillion Biosciences
RhyGaze
Moleculent
Pelage Pharmaceuticals
Sonoma Biotherapeutics
AIRNA
Maven Bio
Ligo Biosciences
Kopra Bio
Viome
Bolt Threads
Superluminal Medicines
Manakin Bio
NeuroDx
Timberlyne Therapeutics
Aera Therapeutics
Converge Bio
Sironax
Tome Biosciences
CellForge
Corxel Pharmaceuticals
Immunai
ImmunoLogic
Odyssey Therapeutics
KAHR Medical
ReNAgade Therapeutics
Mirador Therapeutics
LifeMine Therapeutics